New pill aims to slow deadly lung scarring

This study tests whether an experimental drug called HEC585 can slow the worsening of lung function in people with progressive fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and breathing gets harder over time. About 110 adults will receive either a low dose, high dose, or a placebo for 24 weeks, with an option to continue for up to 96 weeks. The main goal is to see if the drug helps maintain lung capacity compared to a placebo.